Zachary S. Wochok - 12 Jul 2022 Form 4 Insider Report for MARRONE BIO INNOVATIONS INC

Role
Director
Signature
/s/ Linda V. Moore, as attorney in fact
Issuer symbol
N/A
Transactions as of
12 Jul 2022
Net transactions value
$0
Form type
4
Filing time
14 Jul 2022, 20:33:23 UTC
Previous filing
05 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MBII Common Stock Award $0 +429,081 +53635% $0.000000 429,881 12 Jul 2022 Direct F1, F2
transaction MBII Common Stock Disposed to Issuer -429,881 -100% 0 12 Jul 2022 Direct F3
transaction MBII Common Stock Disposed to Issuer -5,000 -100% 0 12 Jul 2022 Held by The Zachary S Wochok & Barbara N Wochok Trust F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MBII Restricted Stock Units Options Exercise $0 -429,081 -100% $0.000000* 0 12 Jul 2022 Common Stock 429,081 Direct F2, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Zachary S. Wochok is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Any unvested restricted stock units became vested and all restricted stock units were delivered to the Reporting Person, pursuant to the grant terms, immediately prior to the change of control transaction (the "Merger") contemplated by the Agreement and Plan of Merger, dated as of March 16, 2022, by and between Bioceres Crop Solutions Corp., BCS Merger Sub, Inc., and Issuer (the "Merger Agreement").
F2 The settlement of restricted stock units is being reported as one award; however, a number of awards of restricted stock units, as reported in prior Forms 4, are being settled. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, upon request, details of the awards previously granted and settled as set forth in this footnote to this Form 4.
F3 Disposed of pursuant to the Merger Agreement in exchange for 37,829 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
F4 Disposed of pursuant to the Merger Agreement in exchange for 440 Ordinary Shares of BIOX having a market value of $9.44 per share on the effective date of the Merger.
F5 Each restricted stock unit represented a contingent right to receive one share of Marrone Bio Innovations, Inc. common stock.
F6 Any unvested restricted stock units vested completely immediately prior to the Merger, and the underlying shares were delivered to the Reporting Person immediately prior to the Merger in accordance with the terms of the grants.